Join Mark Kiel, Founder and CSO of Genomenon, and John Quackenbush, Professor of Computational Biology and Bioinformatics at Harvard T.H. Chan School of Public Health for a candid fireside conversation on use of AI in biomedicine. Bringing optimism about AI’s potential into direct contact with skepticism about what it can truly prove, this discussion puts two distinct perspectives into dialogue - pressure testing what AI can truly contribute to biomedical research and clinical decision-making.In this conversation, John and Mark will cover how evidence is gathered, processed, and structured - and how it’s applied to decisions in research, development, and clinical practice.
Key questions we’ll cover include:
• Is generative AI advancing biomedical knowledge - or just industrializing confirmation bias?
• Are we deploying generative AI in the clinic before we’ve agreed on what counts as evidence?
• If an “insight” can’t be traced back to primary sources, is it useful - or too risky - for hypothesis generation?
• Have we mistaken fluency for understanding - do models generate genuine insight, or do we project insight onto them?
• Will generative AI reduce uncertainty in biomedicine, or mainly repackage it faster?
This session will give you a clear, practical view of where generative AI actually helps across drug development cycle - what it can accelerate (and what it can’t), where the risks show up, and what defensible validation looks like before it informs decisions. Who should attend:
Pharma/biotech professionals applying AI across the drug development cycle - especially teams in discovery and translational science, clinical development and trial strategy, medical affairs/RWE, and bioinformatics/data science - who need a realistic view of what generative AI can support in high-stakes decisions.
SPEAKERS:
Mark Kiel, MD PhD
Chief Scientific Officer
Genomenon
John Quackenbush, PhD
Professor, Computational Biology and Bioinformatics, Department of Biostatistics
Harvard T.H. Chan School of Public Health
Complete the form below to view the webinar recording:
Dr. Mark Kiel is the co-founder and chief scientific officer at Genomenon, where he oversees the company's scientific direction and product development. Mark received his MD/PhD in Clinical Pathology at the University of Michigan. He founded Genomenon to address the challenge of connecting researchers with evidence in the literature to help diagnose and treat patients with rare genetic diseases and cancer.
Genomenon® is a genomic intelligence company transforming patient care by uncovering the genomic drivers of genetic disease and cancer. By combining the power of AI built on a comprehensive genomic dataset with deep scientific expertise, Genomenon delivers structured, actionable insights that support advanced patient diagnosis and accelerate precision medicine development. Its integrated software, data, and services solutions empower biopharma and clinical partners worldwide.
We help provide insights into key genetic drivers of diseases and relevant biomarkers. By working together to understand this data, we enable scientists and researchers to make more informed decisions on programs of interest. To learn more about how we can partner together to find your genomic variant solutions, we invite you to click on the link below.
